The estrogen blockers global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Estrogen Blockers Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The estrogen blockers market size has grown strongly in recent years. It will grow from $8.72 billion in 2023 to $9.35 billion in 2024 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to a rise in the prevalence of prostate cancer, an increase in the prevalence of hormone-related disorders, increase in the adoption of hormone replacement therapy (HRT).
The estrogen blockers market size is expected to see strong growth in the next few years. It will grow to $12.37 billion in 2028 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to the rising prevalence of breast cancer, growing awareness, and screening initiatives, increasing prevalence of estrogen-related conditions globally, and expanding the scope of applications for estrogen blockers beyond cancer treatment. Major trends in the forecast period include advancements in estrogen blocker development, the discovery of novel estrogen blockers with improved efficiency, strategic partnerships among market players, and new product approvals.
Order your report now for swift delivery @
Scope Of Estrogen Blockers Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Estrogen Blockers Market Overview
Market Drivers –
The rising prevalence of breast cancer is expected to propel the growth of the estrogen blocker market going forward. Breast cancer is a type of cancer that originates in the breast tissue, primarily affecting the milk ducts and lobules. It occurs when normal breast cells undergo mutations, leading to uncontrolled growth and the formation of tumors. The prevalence of breast cancer is increasing due to several factors, such as the aging population, lifestyle changes such as higher alcohol consumption and sedentary habits, and increased detection through improved screening and diagnostic techniques. Estrogen blockers help with breast cancer by inhibiting the hormone estrogen, which can promote the growth of certain types of breast cancer cells and slow or stop the growth of hormone receptor-positive breast cancers, thereby aiding in treatment and potentially reducing recurrence. For instance, in January 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2023, an estimated 20,458 cases of breast cancer were diagnosed in females, corresponding to an age-standardized incidence rate of 128.6 cases per 100,000 females. In 2022, an estimated 20,004 cases of breast cancer were diagnosed in females, with an age-standardized incidence rate of 128.2 cases per 100,000 females. Therefore, the rising prevalence of breast cancer is driving the growth of the estrogen blocker market.
Market Trends –
Major companies operating in the estrogen blocker market are focused on developing advanced estrogen blocker drugs, with a combination of AKT (Protein Kinase B) inhibitors and selective estrogen receptor degraders (SERD), to enhance treatment efficacy and address resistance issues in breast cancer therapy. The combination of AKT (Protein Kinase B) inhibitors and selective estrogen receptor degraders (SERDs) is a therapeutic strategy used to treat hormone receptor-positive breast cancer. This approach targets cancer cell survival pathways and degrades estrogen receptors to inhibit tumor growth and overcome resistance to hormonal therapies. For instance, in November 2023, AstraZeneca, a UK-based pharmaceutical industry company, received approval from the U.S. Food and Drug Administration (FDA) for Truqap (capivasertib), an AKT (Protein Kinase B) inhibitor, in combination with Faslodex (fulvestrant), a selective estrogen receptor degrader (SERD). It is approved for treating adult patients with hormone receptor (HR)-positive, HER2-negative locally advanced or metastatic breast cancer who have specific biomarker alterations, namely PIK3CA, AKT1, or PTEN. This approval is significant as it targets patients who have progressed on at least one endocrine-based therapy or experienced recurrence within 12 months after completing adjuvant therapy.
The estrogen blockers market covered in this report is segmented –
1) By Product: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Downregulators (ERDs), Other Products
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By Application: Breast Cancer Treatment, Hormone Replacement Therapy (HRT), Infertility Treatment, Post-Menopausal Osteoporosis, Other Applications
Get an inside scoop of the estrogen blockers market, Request now for Sample Report @
Regional Insights –
North America was the largest region in the estrogen blockers market in 2023. The regions covered in the estrogen blockers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the estrogen blockers market are Pfizer Inc, F. Hoffmann-La Roche AG, Merck & Co. Inc, Novartis AG, Sanofi S.A, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Viatris Inc, Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Pharmaceuticals Ltd., Intas Pharmaceuticals Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Lupin Limited, Glenmark Pharmaceuticals Limited, Alvogen Inc., Alembic Pharmaceuticals Limited, Olema Pharmaceuticals Inc, Cipla Inc, Criterium Inc< /b>
Table of Contents
1. Executive Summary
2. Estrogen Blockers Market Report Structure
3. Estrogen Blockers Market Trends And Strategies
4. Estrogen Blockers Market – Macro Economic Scenario
5. Estrogen Blockers Market Size And Growth
…..
27. Estrogen Blockers Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
Twitter: https://twitter.com/tbrc_info
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
